Beyond traditional clinicopathologic factors, genomic insights from the GPS Mdx test can help distinguish patients with favorable vs unfavorable prostate tumor biology, even among clinically ...
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – ...
A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable improvement in urinary symptoms and flow rate, according to data from three ...
A new study indicated that the Bellmunt Risk Score can help stratify survival outcomes in patients with metastatic castration-resistant prostate cancer. Using data from more than 1700 patients across ...
Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results